Clinical Trial Update: A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma [Phase 3]

View source ↗

Summary

This is an update on a Phase 3 trial evaluating OSI-906 (linsitinib) in locally advanced or metastatic adrenocortical carcinoma. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• OSI-906 (linsitinib) (linsitinib)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Adrenocortical Carcinoma | Phase 3 | Status: COMPLETED